Tumor vasculature targeting following co-delivery of heparin-taurocholate conjugate and suberoylanilide hydroxamic acid using cationic nanolipoplex

Biomaterials

Volumn 33, Issue 17, 2012, Pages 4424-4430

  Kim, Ji young ^a   Shim, Gayong ^b   Choi, Hyun woo ^a   Park, Jooho ^a   Chung, Seung Woo ^a   Kim, Sunil ^a   Kim, Kwangmeyung ^c   Chan Kwon, Ick ^c   Kim, Chan Wha ^b   Kim, Sang Yoon ^c,d   Yang, Victor C ^e,f   Oh, Yu Kyoung ^a   Byun, Youngro ^a,f  

^a Seoul National University   (South Korea)

^b Korea University   (South Korea)

^c Korea Institute of Science and Technology   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

^e UNIVERSITY OF MICHIGAN   (United States)

^f Seoul National University   (South Korea)

Author keywords

Angiogenesis inhibitor; Cationic nanolipoplex; Heparin taurocholate conjugate; Histone deacetylase inhibitor; Tumor vasculature targeting

Indexed keywords

ANGIOGENESIS INHIBITORS; CATIONIC NANOLIPOPLEX; HEPARIN-TAUROCHOLATE CONJUGATE; HISTONE DEACETYLASE INHIBITOR; TUMOR VASCULATURE TARGETING;

COMPLEXATION; DRUG PRODUCTS; LIPOSOMES; ORGANIC ACIDS; PHOSPHOLIPIDS; POLYSACCHARIDES;

TUMORS;

ANTINEOPLASTIC AGENT; CATION; HEPARIN; LIPOPLEX; LIPOSOME; TAUROCHOLIC ACID; VORINOSTAT;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD SAMPLING; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR LOCALIZATION; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CATIONS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DELIVERY SYSTEMS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HEPARIN; HYDROXAMIC ACIDS; INJECTIONS, INTRAVENOUS; LIPOSOMES; MICE; NANOPARTICLES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, SPRAGUE-DAWLEY; SERUM; TAUROCHOLIC ACID; TIME FACTORS; TISSUE DISTRIBUTION;

MUS;

EID: 84862809560     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.02.066     Document Type: Article

References (24)

1. Castelli R., Porro F., Tarsia P. The heparins and cancer: review of clinical trials and biological properties. Vasc Med 2004, 9:205-213.
2. Mousa S.A., Petersen L.J. Anti-cancer properties of low-molecular-weight heparin: preclinical evidence. Thromb Haemost 2009, 102:258-267.
3. Lee E., Kim Y.S., Bae S.M., Kim S.K., Jin S., Chung S.W., et al. Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor. Int J Cancer 2009, 124:2755-2765.
4. Cao Y. Antiangiogenic cancer therapy. Semin Cancer Biol 2004, 14:139-145.
5. Relf M., LeJeune S., Scott P.A., Fox S., Smith K., Leek R., et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997, 57:963-969.
6. Patra C.R., Bhattacharya R., Wang E., Katarya A., Lau J.S., Dutta S., et al. Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res 2008, 68:1970-1978.
7. Abu Lila A.S., Ishida T., Kiwada H. Recent advances in tumor vasculature targeting using liposomal drug delivery systems. Expert Opin Drug Deliv 2009, 6:1297-1309.
8. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46:6387-6392.
9. Ran S., Downes A., Thorpe P.E. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res 2002, 62:6132-6140.
10. Zwaal R.F., Schroit A.J. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997, 89:1121-1132.
11. Zhang Q., Bindokas V., Shen J., Fan H., Hoffman R.M., Xing H.R. Time-course imaging of therapeutic functional tumor vascular normalization by antiangiogenic agents. Mol Cancer Ther 2011, 10:1173-1184.
12. Ma X., Ezzeldin H.H., Diasio R.B. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 2009, 69:1911-1934.
13. Lee M.J., Kim Y.S., Kummar S., Giaccone G., Trepel J.B. Histone deacetylase inhibitors in cancer therapy. Curr Opin Oncol 2008, 20:639-649.
14. Ganslmayer M., Zimmermann A., Zopf S., Herold C. Combined inhibitors of angiogenesis and histone deacetylase: efficacy in rat hepatoma. World J Gastroenterol 2011, 17:3623-3629.
15. Wang S., Chang Y.T. Discovery of heparin chemosensors through diversity oriented fluorescence library approach. Chem Commun (Camb) 2008, 1173-1175.
16. Suh M.S., Shim G., Lee H.Y., Han S.E., Yu Y.H., Choi Y., et al. Anionic amino acid-derived cationic lipid for siRNA delivery. J Control Release 2009, 140:268-276.
17. Lee S., Shim G., Kim S., Kim Y.B., Kim C.W., Byun Y., et al. Enhanced transfection rates of small-interfering RNA using dioleylglutamide-based magnetic lipoplexes. Nucleic Acid Ther 2011, 21:165-172.
18. Marchini C., Montani M., Amici A., Amenitsch H., Marianecci C., Pozzi D., et al. Structural stability and increase in size rationalize the efficiency of lipoplexes in serum. Langmuir 2009, 25:3013-3021.
19. Tros de Ilarduya C., Sun Y., Duzgunes N. Gene delivery by lipoplexes and polyplexes. Eur J Pharm Sci 2010, 40:159-170.
20. Li L., Song H., Luo K., He B., Nie Y., Yang Y., et al. Gene transfer efficacies of serum-resistant amino acids-based cationic lipids: dependence on headgroup, lipoplex stability and cellular uptake. Int J Pharm 2011, 408:183-190.
21. Abu Lila A.S., Ishida T., Kiwada H. Targeting anticancer drugs to tumor vasculature using cationic liposomes. Pharm Res 2010, 27:1171-1183.
22. Meng M., Liu Y., Wang Y.B., Wang J.C., Zhang H., Wang X.Q., et al. Increase of the pharmacological and pharmacokinetic efficacy of negatively charged polypeptide recombinant hirudin in rats via parenteral route by association with cationic liposomes. J Control Release 2008, 128:113-119.
23. Krasnici S., Werner A., Eichhorn M.E., Schmitt-Sody M., Pahernik S.A., Sauer B., et al. Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels. Int J Cancer 2003, 105:561-567.
24. Thurston G., McLean J.W., Rizen M., Baluk P., Haskell A., Murphy T.J., et al. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest 1998, 101:1401-1413.